Dermatology · Milwaukee, WI
NPI
1770748303
Since 2008
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
735 N Water St Ste 830
Milwaukee, WI, 53202
Phone (414) 276-1222
Groups this clinician bills Medicare through
Medicare paid, 2024
$26K
646 services
Medicare patients, 2024
151
Average age 68
Drug cost, 2024
$2.5M
2,151 prescriptions
Company payments, 2025
$5,842
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Erik Alexander was code 17003 (destruction skin lesion), 163 times for 31 patients. In total Erik Alexander billed 646 services in 33 codes, and Medicare paid $26K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-09-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 163 | 31 | $4.88 | $796 |
| 99213 Office E&M - Established | Office | 87 | 58 | $54.32 | $4,726 |
| 99214 Office E&M - Established | Office | 86 | 51 | $83.58 | $7,188 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 77 | 13 | $0.66 | $51.12 |
| 17000 Destruction Skin Lesion | Office | 53 | 41 | $40.87 | $2,166 |
| 17110 Destruction Skin Lesion | Office | 28 | 25 | $67.61 | $1,893 |
| 99204 Office E&M - New | Office | 26 | 26 | $110.15 | $2,864 |
| 96372 Injection Administration | Office | 21 | 12 | $10.62 | $223 |
| 99203 Office E&M - New | Office | 18 | 18 | $66.17 | $1,191 |
| 36415 Venipuncture Blood Collection | Office | 14 | 12 | $8.65 | $121 |
| 11102 Skin Biopsy | Office | 11 | 11 | $53.66 | $590 |
By year: 2022 $33K for 745 services; 2023 $23K for 557 services; 2024 $26K for 646 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 14 | 12 | $8.65 | $121 |
Medicare prescription drug claims, 2024
In 2024, the drug Erik Alexander prescribed most often to Medicare patients was Clobetasol Propionate, with 451 prescriptions and refills. In total Erik Alexander wrote 2,151 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 451 | 481 | 160 | $18K |
| Minocycline Hcl Generic | 155 | 179 | 38 | $3,287 |
| Ketoconazole Generic | 114 | 120 | 39 | $1,765 |
| Triamcinolone Acetonide Generic | 105 | 113 | 40 | $1,855 |
| Tretinoin Generic | 78 | 87 | 28 | $6,664 |
| Prednisone Generic | 70 | 72 | 19 | $187 |
| Metronidazole Generic | 63 | 63 | 21 | $2,809 |
| Rinvoq Upadacitinib | 63 | 69 | Under 11 | $443K |
| Dupixent Pen Dupilumab | 60 | 61 | 12 | $238K |
| Minoxidil Generic | 53 | 95 | 13 | $610 |
| Spironolactone Generic | 53 | 90 | 17 | $705 |
| Humira(Cf) Pen Adalimumab | 50 | 51 | Under 11 | $513K |
| Fluocinolone Acetonide Fluocinolone/Shower Cap | 49 | 49 | 12 | $3,455 |
| Halobetasol Propionate Generic | 45 | 48 | 20 | $3,413 |
| Hydroxychloroquine Sulfate Generic | 45 | 64 | 11 | $914 |
Brand drugs: 415 claims; generic drugs: 1,736 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Erik Alexander $5,842 ($5,842 in general payments such as food, travel and fees) from 21 companies. The largest payer was Sun Pharmaceutical Industries Inc. with $811.
| Company | Payments | Amount |
|---|---|---|
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 42 | $811 |
| Abbvie Inc. ABBV | 42 | $797 |
| Janssen Biotech, Inc. JNJ | 19 | $562 |
| UCB, Inc. UCB.BR | 29 | $555 |
| Regeneron Healthcare Solutions, Inc. REGN | 22 | $471 |
| Pfizer Inc. PFE | 24 | $432 |
| Genzyme Corporation SNY | 11 | $371 |
| Lilly USA, LLC LLY | 17 | $347 |
| Novartis Pharmaceuticals Corporation NVS | 15 | $325 |
| Amgen Inc. AMGN | 15 | $270 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.